Jpmorgan Chase & CO Capricor Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 17,425 shares of CAPR stock, worth $117,618. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,425
Previous 16,680
4.47%
Holding current value
$117,618
Previous $231,000
28.57%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CAPR
# of Institutions
144Shares Held
12.4MCall Options Held
4.99MPut Options Held
5.52M-
Vanguard Group Inc Valley Forge, PA2.31MShares$15.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$11 Million0.0% of portfolio
-
State Street Corp Boston, MA1.47MShares$9.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA963KShares$6.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY551KShares$3.72 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $164M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...